NCT04128748 2025-12-17
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT04990102 2025-07-29
Phase IB/II of CPX-351 for Relapse Prevention in AML
Georgetown University
Phase 1/2 Recruiting
NCT07008638 2025-07-09
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1/2 Recruiting
NCT04049539 2025-03-05
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting